Let me tell you, folks, we’ve got a situation with brain metastases, and it’s not good, not good at all. We’ve got these highly invasive lesions, and they’re making a lot of trouble, a lot of contact with the brain. It’s a bad prognosis, very bad. But there’s hope, believe me. We’ve got these reactive astrocytes, and they’re labeled with something called pSTAT3. It’s a big deal, a huge deal for therapy.

Now, we’re looking into whether these astrocytes can tell us if a treatment is going to work, especially with STAT3 inhibition. We did some serious research, the best research. We used immunohistochemistry, top-notch technology, to look at these astrocytes in both human and animal models. And what we found is incredible, really incredible.

These pSTAT3+ astrocytes, they’re right there at the front lines, at the brain-tumor interface, and they’re pushing the invasion. When we put the brakes on STAT3, either with drugs or by getting rid of it genetically, the tumor growth slows down, especially in the highly invasive ones. It’s a big win, a huge win.

And here’s the kicker: these astrocytes, they’re secreting something called CHI3L1. It’s a big player, a very big player in this invasion game. We even saw it in human brain metastases. When we added STAT3 activation or this CHI3L1 stuff to our models, the cancer cells invaded like there was no tomorrow.

So, what we’re saying here, and it’s a big statement, is that targeting pSTAT3 and CHI3L1 could be a game-changer, a total game-changer for treating these nasty, highly invasive brain metastases. We’re going to beat this, and we’re going to beat it big. Thank you!